The novel nanosomal docetaxel lipid suspension (NDLS)-based chemotherapy was effective and well tolerated in managing breast cancer in all settings. Furthermore, NDLS is being evaluated prospectively in patients with triple-negative breast cancer (ClinicalTrials.gov identifier: NCT03671044)
The authors thank Mr Shreekant Sharma, MPharm, ISMPP CMPPTM (Lambda Therapeutic Research Ltd., Ahmedabad, Gujarat, India) for providing writing assistance and Dr Venugopal Madhusudhana, MBBS, EPBM, ISMPP CMPPTM (Lambda Therapeutic Research Ltd., Ahmedabad, Gujarat, India) for additional editorial assistance for the development of this manuscript. The authors also thank the clinical data management and biostatistics department of Lambda Therapeutic Research Ltd. for their contribution in the preparation of the statistical analysis report in this retrospective data collation and analysis.
SS, RP, GB, SKDM performed the research, were involved in the acquisition of data, critically revised the manuscript for important intellectual content, and approved the final manuscript. NJ, DB, MAK and IA designed the study, were involved in the data interpretation, critically revised the manuscript for important intellectual content, and approved the final manuscript. All authors made substantial contributions to this study and agree to be accountable for all aspects of the work.
This study was funded by an unrestricted research grant by Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India.
Drs Mujtaba A Khan, Deepak Bunger and Nisarg Joshi are employees of Intas Pharmaceuticals Ltd., India, and the product being mentioned is manufactured and marketed by Intas Ltd. Dr Imran Ahmad is an employee of Jina Pharmaceuticals Inc., USA. The authors report no other conflicts of interest in this work.
1. Ghoncheh M, Pournamdar Z, Salehiniya H. Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev. 2016;17(S3):43–46. doi:10.7314/APJCP.2016.17.S3.43
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
3. National Institute for Cancer Prevention and Research. Globocan 2018: India Factsheet. Available from: http://cancerindia.org.in/globocan-2018-india-factsheet/. Accessed April 21, 2020.
4. Crown J, O’Leary M, Ooi WS. Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist. 2004;9Suppl 2(S2):24–32. doi:10.1634/theoncologist.9-suppl_2-24
5. Taxotere® Prescribing Information. sanofi-aventis U.S. LLC, NJ 08807. Revised May, 2010.
6. Amat S, Bougnoux P, Penault-Llorca F, et al. Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer. 2003;88(9):1339–1345. doi:10.1038/sj.bjc.6600916
7. von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30(15):1796–1804. doi:10.1200/JCO.2011.38.8595
8. Weiszhár Z, Czúcz J, Révész C, et al. Complement activation by polyethoxylated pharmaceutical surfactants: cremophor-EL, Tween-80 and Tween-20. Eur J Pharm Sci. 2012;45(4):492–498. doi:10.1016/j.ejps.2011.09.016
9. Pritchett W, Kinsley K. Benefits and risks of fosaprepitant in patients receiving emetogenic regimens. Clin J Oncol Nurs. 2016;20(5):555–556. doi:10.1188/16.CJON.555-556
10. Fumoleau P, Tubiana-Hulin M, Soulie P, et al. A dose finding and pharmacokinetic (PK) Phase I study of a new formulation of docetaxel (D) in advanced solid tumors. [abstract]. Ann Oncol. 1998;9(Suppl. 2):101.
11. Ten Tije AJ, Verweij J, Loos WJ, Sparreboom A. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet. 2003;42(7):665–685. doi:10.2165/00003088-200342070-00005
12. Coors EA, Seybold H, Merk HF, Mahler V. Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol. 2005;95(6):593–599. doi:10.1016/S1081-1206(10)61024-1
13. Schwartzberg LS, Navari RM. Safety of polysorbate 80 in the oncology setting. Adv Ther. 2018;35(6):754–767. doi:10.1007/s12325-018-0707-z
14. FDA Drug Safety Communication (2014, June 20). FDA warns that cancer drug docetaxel may cause symptoms of alcohol intoxication after treatment. Available From: https://www.fda.gov/Drugs/DrugSafety/ucm401752.htm. Accessed April 21, 2020.
15. Mirza A, Mithal N. Alcohol intoxication with the new formulation of docetaxel. Clin Oncol (R Coll Radiol). 2011;23(8):560–561. doi:10.1016/j.clon.2011.04.010
16. Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European organization for research and treatment of cancer investigational drug branch for breast cancer. J Clin Oncol. 1997;15(9):3149–3155. doi:10.1200/JCO.19220.127.116.1149
17. Jung JW, Choi YH, Park CM, et al. Outcomes of corticosteroid prophylaxis for hypersensitivity reactions to low osmolar contrast media in high-risk patients. Ann Allergy Asthma Immunol. 2016;117(3):304–309.e301. doi:10.1016/j.anai.2016.07.010
18. Alken S, Kelly CM. Benefit risk assessment and update on the use of docetaxel in the management of breast cancer. Cancer Manag Res. 2013;5:357–365. doi:10.2147/CMAR.S49321
19. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8(7):1263–1268. doi:10.1200/JCO.1918.104.22.1683
20. Ahmad A, Sheikh S, Taran R, et al. Therapeutic efficacy of a novel nanosomal docetaxel lipid suspension compared with taxotere in locally advanced or metastatic breast cancer patients. Clin Breast Cancer. 2014;14(3):177–181. doi:10.1016/j.clbc.2013.09.011
21. Ashraf M, Sajjad R, Khan M, et al. 156P Efficacy and safety of a novel nanosomal docetaxel lipid suspension (NDLS) as an anti cancer agent-a retrospective study. Ann Oncol. 2016;27(suppl_9). doi:10.1093/annonc/mdw579.008.
22. Murali A, Gupta S, Pendharkar D. Efficacy and tolerability of nanoparticle docetaxel lipid suspension. J Clin Oncol. 2018;36(15_suppl):e14542–e14542. doi:10.1200/JCO.2018.36.15_suppl.e14542
23. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
24. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed April 21, 2020.
25. National Comprehensive Cancer Network (NCCN). Breast Cancer Guidelines 2019.
26. Cardoso F, Senkus E, Costa A, et al. 4th ESO–ESMO international consensus guidelines for advanced breast cancer (ABC 4)†. Ann Oncol. 2018;29(8):1634–1657. doi:10.1093/annonc/mdy192
27. Ahmad A, Sheikh S, Ali SM, et al. Development of aqueous based formulation of docetaxel: safety and pharmacokinetics in patients with advanced solid tumors. J Nanomed Nanotechnol. 2015;6(3):1.
28. Naik R, Khan MA. Doceaqualip in a patient with prostate cancer who had an allergic reaction to conventional docetaxel: a case report. Mol Clin Oncol. 2017;6(3):341–343. doi:10.3892/mco.2017.1147
29. Prasanna R, Bunger D, Khan MA. Efficacy and safety of DoceAqualip in a patient with locally advanced cervical cancer: a case report. Mol Clin Oncol. 2018;8(2):296–299. doi:10.3892/mco.2017.1519
30. Vyas V, Joshi N, Khan M. Novel docetaxel formulation (NDLS) in low cardiac reserve ovarian cancer. Open Access J Cancer Oncol. 2018;2(2):000122.
31. Gupta S, Pawar SS, Bunger D. Successful downstaging of locally recurrent penile squamous cell carcinoma with neoadjuvant nanosomal docetaxel lipid suspension (NDLS) based regimen followed by curative surgery. BMJ Case Rep. 2017;2017.
32. Rajappa S, Joshi A, Doval DC, et al. Novel formulations of docetaxel, paclitaxel and doxorubicin in the management of metastatic breast cancer. Oncol Lett. 2018;16(3):3757–3769. doi:10.3892/ol.2018.9057
33. Spring L, Greenup R, Reynolds K, Smith BL, Moy B, Bardia A. Pathological complete response after neoadjuvant chemotherapy predicts improved survival in all major subtypes of breast cancer: systematic review and meta-analyses of over 18,000 patients. Presented at the 2016 AACR Ann Meeting. 2016. Abstract 1439.
34. Li S, Wei W, Jiang Y, et al. Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer. Drug Des Devel Ther. 2018;12:3085–3093. doi:10.2147/DDDT.S171534
35. Zuradelli M, Gullo G, Walshe J, et al. 446 docetaxel, carboplatin and trastuzumab (TCH) as Neoadjuvant (neoadj) therapy in patients (pts) with HER2-positive (HER2+) Operable Breast Cancer (BrCa). Eur J Cancer. 2012;48:S177. doi:10.1016/S0959-8049(12)70511-7
36. Tiwari A, Gogia A, Deo S, et al. Retrospective study of efficacy and safety of neoadjuvant docetaxel, carboplatin, and trastuzumab in HER2-positive locally advanced and oligometastatic breast cancer: an Indian experience. Indian J Cancer. 2017;54(1):343–346. doi:10.4103/ijc.IJC_152_17
37. Kolberg H-C, Akpolat-Basci L, Stephanou M, Hannig C, Liedtke C. Neoadjuvant chemotherapy with docetaxel, carboplatin, and weekly trastuzumab (TCH) activity in HER2-positive early breast cancer: results after a median follow-up of 4.5 years. J Clin Oncol. 2015;33(28_suppl):140. doi:10.1200/jco.2015.33.28_suppl.140
38. Martin M. Docetaxel, doxorubicin and cyclophosphamide (the TAC regimen): an effective adjuvant treatment for operable breast cancer. Womens Health. 2006;2(4):527–537. doi:10.2217/17455057.2.4.527
39. Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006;24(34):5381–5387. doi:10.1200/JCO.2006.06.5391
READ FULL ARTICLE From Dovepress